We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.00 | 0.15% | 12,188.00 | 12,186.00 | 12,190.00 | 12,258.00 | 12,114.00 | 12,114.00 | 678,296 | 12:56:28 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.75 | 189.06B |
From May 2019 to May 2024
By Josh Beckerman
Switzerland-based biotechnology company ADC Therapeutics SA has filed for an initial public offering.
ADC focuses on hematological malignancies and solid tumors.
The company plans to trade on the New York Stock Exchange under symbol ADCT. The filing lists an amount of $150 million.
Auven Therapeutics owns 42.7% stake of ADC. AstraZeneca PLC (AZN) owns 7.1%.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
September 06, 2019 20:11 ET (00:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
